Lessons Learnt, and Still to Learn, in Stem Cell Trials

This episode is sponsored by Bio-Techne. While advances in stem cell science have led to an increasing number of stem cell-based therapies entering clinical trials, the field is still relatively immature. Thus, these first-in-human trials are using pioneering approaches unique unto themselves, leaving scientists, physicians, and regulators to assess the best approaches for a specific therapy and/or disease.  In this episode of the podcast, Martin Pera is joined by physician-scientists Roger Barker and Rajesh Rao who have and are leading stem cell-based trials to discuss some of the critical aspects of the process and reflect on the “lessons learnt” during their translational journey.  Roger Barker, a pioneer in developing cell therapies for Parkinson’s disease, is a Professor of Clinical Neuroscience at the University of Cambridge and Consultant Neurologist at the Addenbrooke’s Hospital Cambridge. He is a Principal Investigator in the Medical Research Council (MRC) – Wellcome Trust Stem Cell Institute in Cambridge and Director of the MRC-funded UK Regenerative Medicine Platform Stem and Engineered Cell Hub. Roger is a current ISSCR Board Member, former chair of the ISSCR’s Clinical Translation Committee and a Fellow of the Academy of Medical Sciences.Rajesh Rao is an ophthalmologist and the Leonard G Miller Professor of Ophthalmology & Visual Sciences at the University of Michigan; Director of Retina Service at VA Ann Arbor Health System; and the Leslie H. and Abigail S. Wexner Emerging Scholar at the A. Alfred Taubman Medical Research Institute. Dr. Rao is currently running a cell replacement therapy for macular degeneration and is the current chair of the ISSCR’s Clinical Translation Committee.GuestsRoger Barker, MBBS, PhD, University of Cambridge, UKRajesh Rao, MD, University of Michigan, USAHostMartin Pera, PhD, Editor-in-Chief, Stem Cell Reports and The Jackson LaboratoryTwitter: @martinperaJAXSupporting ContentLessons learnt, and still to learn, in first in human stem cell trials, Barker et al, Stem Cell Reports (2022)About Stem Cell ReportsStem Cell Reports is the open access journal of the ISSCR for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians. Twitter: @StemCellReportsAbout ISSCRWith more than 4,600 members from 75+ countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsJack Mosher, Scientific AdvisorVoice WorkBen Snitkoff